Co-expression of NF-κB-p65 and phosphorylated NF-κB-p105 is associated with poor prognosis in surgically resectable non-small cell lung cancer
Open Access
- 24 January 2018
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 22 (3), 1923-1930
- https://doi.org/10.1111/jcmm.13476
Abstract
Nuclear factor-kappa B (NF-κB) as a prognostic marker remains unclear in non-small cell lung cancer (NSCLC). Here, we studied NF-κB-p65 (p65) expression and phosphorylated NF-κB-p105 (p-p105) expression in NSCLC and correlated the finding with overall survival (OS) and clinicopathological features. A total of 186 archival samples from patients with surgically resectable NSCLC were probed with p65 and p-p105 (Ser 932). The p65-positive expression and p-p105-positive expression were defined as distinct nuclear p65 and cytoplasmic p-p105 labelling in at least 1% of tumour cells, respectively. The positive staining of p65 alone, p-p105 alone and co-expression of p65 and p-p105 were observed in 61 (32.8%), 90 (48.4%) and 35 (18.8%) patients, respectively. Co-expression of p65 and p-p105 but not of either p65 or p-p105 alone was associated with a poor prognosis. Patients with co-expression of p65 and p-p105 had a shorter OS than others, median OS 26.5 months versus 64.1 months, HR 1.85 (95% CI: 1.18–2.91), P = 0.007. There was no statistically significant association between clinicopathological characteristics and either p65 or p-p105 alone or co-expression of p65 and p-p105. This indicates that co-expression of p65 and p-p105 was a poor prognostic factor, and pathologic studies of NF-κB expression could include multiple pathway components in NSCLC.Keywords
Funding Information
- National Natural Science Foundation of China (81372599)
- Fujian Provincial Health and Family Research Talent Training Program (2015-ZQN-ZD-9)
- Natural Science Foundation of Fujian Province (2015J01434)
- National Clinical Key Specialty Construction Program of China
This publication has 21 references indexed in Scilit:
- NF-κB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IκBα pathwayOncology Reports, 2012
- Epithelial nuclear factor-κB signaling promotes lung carcinogenesis via recruitment of regulatory T lymphocytesOncogene, 2011
- Requirement of the NF-κB Subunit p65/RelA for K-Ras–Induced Lung TumorigenesisCancer Research, 2010
- The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancerBritish Journal of Cancer, 2008
- Shared Principles in NF-κB SignalingCell, 2008
- Potential biomarkers involving IKK/RelA signal in early stage non‐small cell lung cancerCancer Science, 2008
- Combined Prognostic Value of Both RelA and IκB-α Expression in Human Non–Small Cell Lung CancerAnnals of Surgical Oncology, 2007
- p50 Nuclear Factor-κB Overexpression in Tumor-Associated Macrophages Inhibits M1 Inflammatory Responses and Antitumor ResistanceCancer Research, 2006
- Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesionsCancer, 2006
- Expression of Nuclear Factor-κB and Its Clinical Significance in Nonsmall-Cell Lung CancerThe Annals of Thoracic Surgery, 2006